LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List

Stock News

2025/12/08

LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the "National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:

In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1163080994"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163080994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163080994?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163080994","market":"fut","top_or_hot":-1,"title":"LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)\" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:</p>\n<p>In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA (01513) Products Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)\" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:</p>\n<p>In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1163080994","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163080994","pubTimestamp":1765188385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01513":"丽珠医药"},"translate_title":"丽珠医药(01513)纳入国家报销药品目录的产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)\" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:\nIn 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}